Dato-DXd (Trop2-directed ADC)
HR+/HER2- Metastatic Breast Cancer
Sponsor AstraZeneca
930 Enrollment Target
175 Trial Sites
5 Countries
April 2026 Est. Completion
About This Trial
Antibody-drug conjugate targeting Trop2 with novel topoisomerase I inhibitor payload.
Primary Endpoints
- Progression-free survival
- Overall survival
Latest Update
February 2026
Met primary PFS endpoint with 6.9 month improvement vs chemotherapy. FDA filing imminent.